RxDoctor Payments Data

Shaikh Hoque, MD

Nephrology · Nashua, NHNPI 1508849886

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Lilly USA, LLC at 39.8% of the total. 2025 is the largest year on record at $463, more than ten times the $36 reported in 2019.

$740in general payments, 2019–2025

Across 40 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$295
  • AstraZeneca$261
  • Novo Nordisk$64
  • Ardelyx, Inc.$33
  • Otsuka America Pharmaceutical, Inc.$19
  • Novartis$18
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$740 in reported general payments places this provider in the 80th percentile of 33 nephrology providers in New Hampshire.

See all nephrology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$181,062
Medicare patients
287
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol222$258,208
JardianceEmpagliflozin28$41,316
EntrestoSacubitril/Valsartan13$11,544
Sodium Polystyrene Sulfonate36$4,003
Calcitriol142$2,988
Doxazosin Mesylate97$1,717
Amlodipine Besylate188$1,585
Gentamicin Sulfate33$1,578
Torsemide41$1,187
Sevelamer Carbonate18$1,166
Irbesartan49$1,122
Potassium Chloride33$1,066
Chlorthalidone60$976
Carvedilol84$856
Losartan Potassium119$841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$261$258,208222 claims
Boehringer IngelheimJardiance$17$41,31628 claims
NovartisEntresto$18$11,54413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 nephrology providers in New Hampshire.

Other nephrology in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →